Deutivacaftor / Tezacaftor / Vanzacaftor (2) – Alyftrek®
Cystic fibrosis, at least one non-Class I mutation, aged ≥ 6 years
Characteristics
| Start date | 01.07.2026 |
|---|---|
| Resolution | 17.12.2026 – active procedure |
| INN | Deutivacaftor/Tezacaftor/Vanzacaftor |
| Brand name | Alyftrek® |
| Pharm. company | Vertex Pharmaceuticals (Ireland) Limited |
| G-BA Procedure ID | D-1352 |
| Therapeutic area | Metabolic diseases |
| Reason for procedure | Reassessment: Loss of orphan status |
Associated procedures
<< List of all resolutions